Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars

Core Insights - Eli Lilly reported mixed results for the fourth quarter, with strong sales from its weight loss drug Zepbound and diabetes drug Mounjaro, but lower realized prices impacting overall performance [1][2] - The company has lowered its 2024 revenue guidance due to expectations not being met for demand in its key drug segments [2] - Despite the challenges, Eli Lilly's quarterly earnings exceeded Wall Street estimates, although sales fell slightly short [2][6] Financial Performance - For the fourth quarter, Eli Lilly posted revenue of $13.53 billion, representing a 45% increase year-over-year [3] - The net income for the fourth quarter was $4.41 billion, or $4.88 per share, compared to $2.19 billion, or $2.42 per share, from the previous year [4] - Adjusted earnings per share were reported at $5.32, surpassing the expected $4.95, while revenue fell just short of the expected $13.57 billion [6] Future Guidance - Eli Lilly provided fiscal 2025 profit guidance of $22.05 to $23.55 per share, aligning with analyst expectations [3] - The company reiterated its fiscal 2025 sales guidance, projecting between $58 billion and $61 billion [3]